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Abstract
Background The ﬁrst International Society of Atopic Dermatitis (ISAD) global meeting dedicated to atopic dermatitis
(AD) in Sub-Saharan Africa (SSA) was held in Geneva, Switzerland in April 2019. A total of 30 participants were present
at the meeting, including those from 17 SSA countries, representatives of the World Health Organization (WHO), the
International Foundation for Dermatology (IFD) (a committee of the International League of Dermatological Societies,
ILDS www.ilds.org), the Fondation pour la Dermatite Atopique, as well as specialists in telemedicine, artiﬁcial intelligence
and therapeutic patient education (TPE).
Results AD is one of the most prevalent chronic inﬂammatory skin diseases in SSA. Besides neglected tropical diseases
(NTDs) with a dermatological presentation, AD requires closer attention from the WHO and national Departments of Health.
Conclusions A roadmap has been deﬁned with top priorities such as access to essential medicines and devices for AD
care, in particular emollients, better education of primary healthcare workers for adequate triage (e.g. better educational
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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materials for skin diseases in pigmented skin generally and AD in particular, especially targeted to Africa), involvement of
traditional healers and to a certain extent also patient education, bearing in mind the barriers to effective healthcare faced
in SSA countries such as travel distances to health facilities, limited resources and the lack of dermatological expertise. In
addition, several initiatives concerning AD research in SSA were discussed and should be implemented in close collabora-
tion with the WHO and assessed at follow-up meetings, in particular, at the next ISAD meeting in Seoul, South Korea and
African Society of Dermatology and Venereology (ASDV) meeting in Nairobi, Kenya, both in 2020.
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Introduction
In 2018, the ISAD recognized the need to actively involve more
sub-Saharan African dermatologists in the society activities after
it was realized that the African continent was under-represented
at the well-attended 9thISAD Georg Rajka Symposium in
Utrecht. In retrospect, Africa has been an important target conti-
nent for the Society.
In order to advance the involvement of the ISAD in Africa, a
meeting was organized in Geneva (Fig. 1) to identify research
and intervention priorities in Africa and initiate African-led pro-
jects for AD (research and care) with the help of international
health organizations as the main objectives. Dr Matshidiso
Moeti, the WHO regional representative for Africa (Brazzaville,
Republic of Congo), appointed Prof Mamadou Ball (Nouak-
chott, Mauritania), a dermatologist and former WHO staff
member to present the inaugural lecture; ‘Overview of health
challenges including skin health in SSA’. The IFD/ILDS was rep-
resented by its chair, Dr Claire Fuller (United Kingdom). The
Fondation pour la Dermatite Atopique (Laboratoires Pierre
Fabre), already active in western/central francophone Africa, was
an early and essential supporter of the ISAD initiative.
The WHO position on the African Region (AFRO)
neglected tropical diseases (NTDs) with skin
manifestations and chronic skin non-
communicable diseases including AD
WHO/AFRO countries are characterized by an increase in
healthy life expectancy from 50.9 to 53.8 years between 2012
and 2015 (highest increase in any WHO Region). The burden of
disease is driven by communicable and non-communicable con-
ditions and violence/injuries. Lower respiratory conditions,
HIV/AIDS and diarrhoeal diseases represent the top causes of
both morbidity and mortality.1 The health system performance
assessment indicates that AFRO countries are performing subop-
timally at 49% of their possible level of functionality.2 The chal-
lenging situation of NTD control was illustrated by the story of a
young shepherd with a mycetoma seen with a large, thick plaque
after a disease course of 10 years duration. NTDs are typically
diseases of poverty, affecting underserved people with poor
health service coverage, emphasizing inaccessibility (geographi-
cal and financial), delay in reporting to health facilities and scar-
city of tools (medicines and diagnostic tests). The WHO list of
NTDs includes 20 conditions amongst which 5 are amenable to
control by preventive chemotherapy through mass medicine
administration (MMA) (onchocerciasis; lymphatic filariasis;
schistosomiasis; soil-transmitted helminthiasis; and blinding tra-
choma) with the 15 other diseases requiring case management
(CM). Amongst this CM list, nine are considered as skin NTDs
(including leprosy, Buruli ulcer, leishmaniasis, scabies, myce-
tomas and yaws). Co-endemicity is the rational basis for the ‘in-
tegrated’ approach to control skin-related NTDs, since
combining the management of related diseases leads to more
efficient use of resources.3
The WHO is supporting countries to ensure (1) the availabil-
ity and the affordability of existing tools and intensifying their
use; (2) the field level capacities to manage target diseases is pro-
vided; and (3) the rapid development and implementation of
innovative control tools (diagnostics, treatment tools and strate-
gies for public health interventions). In addition, the WHO is
giving support for countries to develop master plans and to
adapt regional strategies and guidelines. The WHO is providing
manuals to help health workers recognize NTDs through
changes on the skin.4–6
For other non-NTD chronic skin conditions such as AD, the
lack of dermatologists and dermatology clinics, the probable
underestimated low burden of disease and low mortality in this
group precludes WHO prioritization. For AD as well as asthma
and allergic rhinitis, the available data indicate prevalence rates
for some countries similar to European Union countries. AD
and asthma are common inflammatory disease seen both in pri-
mary care and especially dermatology clinics/hospitals. There is
a strong need of better epidemiological and burden of disease
data and of programs of training for common dermatological
conditions seen in primary care. The grouping of AD under
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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‘eczemas’ in the WHO non-NTD chronic conditions list, which
probably includes many cases of contact allergy and other
eczematous conditions, remains a problem, compounded by the
lack of validated diagnostic criteria for AD adapted to black Afri-
can skin and environments. In addition to difficulties with diag-
nosis, barriers to the implementation of therapeutic education
include, as for NTDs, poverty, inadequate facilities, shortage of
skilled health workers, illiteracy, language and cultural barriers.
The possibility of following an ‘integrated’ approach, as for
NTDs, by better education of primary healthcare workers,
including using digital technologies, may improve appropriate
primary patient care and patient referral to specialists when
necessary.7
Whilst recognizing the validity of the WHO NTD ‘integrated’
approach, participants favoured a greater emphasis on dermato-
logical conditions in general and also discussed AD integration
with common-related disorders such as asthma and rhinitis. For
the WHO NTDs integrative approach, special attention should
be paid to campaigns against scabies to differentiate it from AD.
The discussion following the presentation suggested that the
WHO should support country’s plans to develop AD prevention
and education strategies, including access to cheaper emollient
therapies as well as innovative digital technologies such as tele-
medicine. The discussion also emphasized that improving the
knowledge of primary care providers, including traditional
healers, should be considered as a primary target, a point also
emphasized by the IDF. For implementation of this policy, the
WHO requests a bottom-up approach with the involvement of
national African dermatologists, lobbying national Ministers of
Health to raise the issue of neglected common chronic skin dis-
eases at future WHO Regional Committee meetings. Ministers
should be briefed about the high prevalence of skin diseases and
paradoxically the lack of WHO publications on this subject.
Survey on AD in Sub-Saharan Africa
In order to assess the current situation of AD in SSA, an online
questionnaire-based survey was conducted between Oct 2018
and Jan 2019. An invitation to complete the survey was sent to
105 colleagues from African countries through the personal net-
works of the organizers. The survey was done in three different
languages: English, French and Portuguese. Data were collected
using SurveyMonkeyTM. A total of 90 responses from 23 coun-
tries (52 Francophone, 23 Anglophone and 15 Lusophone) were
obtained (Fig. 2a) corresponding to an 85% response rate. Fifty-
two responders were board certified dermatologists (58%) and
resident dermatologists in training (11 participants, 12%), but
nine paediatricians and six general practitioners, most with
training in allergy, two allied health workers and a patient serv-
ing as an ambulance paramedic (South Africa) also completed
the survey. Some of the responders had a mixed training
Figure 1 Group photo, Novotel Geneve Centre.
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(paediatrics and allergy 4, dermatology and allergy 3, dermatol-
ogy and paediatric dermatology 2).
The majority of responders (69.7%) were seeing 1–10 AD
patients/week in the setting of a regional/central centre. Most
were using emollients/moisturizers and topical corticosteroids.
For systemic therapies, oral antihistamines ranked first before
oral antibiotics (given mostly for secondary infections), systemic
corticosteroids and methotrexate (Fig. 2b). Guidelines from
dermatology or allergy societies (South Africa, foreign countries)
were used by roughly half of the practitioners.
Problems related to AD that were considered common or
very common in Africa included: lack of medication, lack of
information about the disease amongst the local population
and primary care workers, limited access to medical care
and lack of proper training of healthcare professionals. A
striking feature was the lack of education materials and
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educational programs for patients with AD in most African
countries.
The survey supported the impression that AD is a growing
problem in Africa.8 The acceptance of a chronic disease that
needs continuous care is a difficult concept for patients and their
carers.
The discussion that followed revealed that a common
problem was the unavailability of first-line treatments such as
emollients, because of the dependence on expensive imported
products. Self-administered alternative medicines including
mostly herbal medications were commonly used, as well as
consulting traditional healers. It was highlighted that the
widespread use of alternative/traditional medicines, combined
low cost, more patient-practitioner dialogue and better cul-
tural acceptability. Participants reported cases of severe ery-
throdermic presentations of AD after traditional herbal
medicines applications (Fig. 3a). Some additional aspects were
highlighted in the SSA context: self-medication with high
doses of vitamins, lack of availability of bathing facilities and
limiting the use of petrolatum-based products on the skin
due to polycyclic aromatic hydrocarbon contamination fears
and cancer risk, but also due to the fire hazard with paraffin
emollients.9,10
Summary of the major issues concerning AD in
SAA
Clinical aspects
In general, the clinical aspects shown by the different presenters
were similar to what is observed in the rest of the world. How-
ever, some clinical features were highlighted as more common
such as a higher frequency of palmar hyperlinearity and liche-
noid papular lesions (papular/follicular AD) (Fig. 3b), prurigo-
type lesions, extensor involvement (reverse pattern), frequent
facial involvement and severe bacterial superinfection (Fig. 3c).
The impact of neglected superinfection on morbidity/mortality
is not known.
The most used diagnostic criteria are those of the UK
working party, which have not been validated for African
populations except in two studies done in Ethiopia and
South Africa, both of which found poor positive predictive
values for the criteria.11,12 Adapted, validated and clinician-
friendly criteria are needed for research and clinical use.13
Adaptation of existing scoring systems such as SCORAD14,15
is being developed for black skin.16
The major differential diagnoses cited by participants besides
contact eczema are scabies, insect bites, actinic lichen planus,
Figure 3 (a) erythroderma after herbal therapy, (b) papular AD and (c) severe bacterial superinfection in childhood AD.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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HTLV1 infective dermatitis, HIV infection, hand foot and
mouth disease (for flares).
Several participants discussed the difficulty of long-term AD
management of African patients seeking a cure, who do not
accept the concept of chronic disease, a problem already noted
worldwide. Corticosteroid phobia also exists in SSA, but the
extent of the problem needs evaluation.17
During the discussion of the clinical aspects of AD, the com-
mon use of rubbing with abrasive ‘washing nets’ to exfoliate and
smoothen the skin was described and may explain some cases of
severe lichenification and possibly hyperpigmentation. There
was an expressed need for more in-depth studies of the AD phe-
notype in black skin in African populations,18,19 the expectations
of the African populations, and allergy testing to identify local
relevant allergens, differentiate AD from contact dermatitis or to
diagnose additional contact dermatitis in AD patients.20
Genetic risk mechanisms and environmental effects
Despite reduced filaggrin breakdown products having been
shown in one study,21 no equivalent of the null mutations in the
gene encoding filaggrin, seen in European and Asian people, can
to date explain a skin barrier defect in African black skin. Strong
genetic risks for AD in Africa have not yet been identified.22
Other skin barrier components associated or not with pigmenta-
tion such as redox status, which has been shown to be increased
in high versus low phototype skin,23 were discussed.
The patient environment at the onset of AD in African popu-
lations is clearly different from that of populations of African
ancestry born and living in developed countries. The following
habits and facts were cited in the discussion: removal of vernix
in neonates, shea butter massage in infants, insecticide use and
exposures, endemic parasitic infections, type of foods,24 use of
irritating plants, overall bad sanitation and scarce access to water
but increased use of harsh detergents, differences in prevalence
between urban and rural areas with AD more prevalent in urban
areas as noted in developed nations.25
The spectrum of clinically relevant common allergens/atopens
across the SSA is poorly documented. Patch/prick testing with
standard commercial series, developed for northern regions such
as the European series, may be inadequate and provide unreli-
able data.
Concerning cytokine imbalance and microbiome, studies are
lacking in African skin. Early life changes in skin, gut and airway
microbiome can precede AD, food allergy and asthma.26 As the
skin microbiome is also influenced by such factors as ethnicity,
climate, UV exposure and lifestyle factors, future studies of Afri-
can AD skin microbiome may yield novel regional variations. It
was also noted that a butyrate-rich diet (enriched in fibre-rich
foods and milk fat) shaped the gut microbiome and reduced AD
incidence.27 A recent study in South African children demon-
strated differences in gut microbiome composition between rural
children with AD compared with their healthy counterparts.28
Recent reports have indicated a multipolarity of immune axes
in AD. Notably, Asian AD skin phenotypes included psoriatic
features that were associated with a strong Th17 immune axis.29
It was noted by some participants that a similar phenotype in
African patients has been observed in clinical practice, indicating
the need for identifying possibly novel African immune endo-
types.
Epidemiology, health resources, telemedicine and
therapeutic patient education (TPE)
As investigated in a recent systematic review, only four studies
have addressed changes in population prevalence of AD in Africa
using validated instruments such as those used by the Interna-
tional Study of Asthma and Allergies in Childhood (ISAAC).
The period prevalence of AD in adolescents increased in some
SSA countries (Ethiopia, Kenya and South Africa) with a
decrease in prevalence in Nigeria over the same period.30 Over-
all, the existing figures for life prevalence of AD are comparable
to those found in developed countries. Relevant atopen/allergen
exposures are largely unknown. Sensitization to birch pollen has
been detected in parts of Africa (Zimbabwe, Tanzania and South
Africa) where there are no birch trees.31 At a molecular level,
these reactions are directed against profilin Bet v 2 an ubiquitous
plant allergen cross-reacting with local plants and not to Bet v 1
as seen in clinically relevant allergies in Europe. Mouse sensitiza-
tion seems common in AD patients when assessed at a molecular
level by Mus m1 detection,32 but its relevance to AD has not yet
been established.
Access to specialists in dermatology is difficult in nearly all
countries, with an average of one dermatologist for 1–2 million
inhabitants. Public health systems are usually articulated in three
levels; local, regional and national and most dermatologists prac-
tice in the capital cities, with some exceptions such as Burkina
Faso. In general, there is inadequate public health infrastructure
and either insufficient resources or poor management of natural
resources.
Concerning the training of dermatologists, the most endowed
country represented was South Africa with 171 certified derma-
tologists followed by Ethiopia (approximately 100) and Co^te
d’Ivoire with 72 (Table 1).
The question of training abroad was discussed, but local train-
ing was found preferable if young trainees can stay in their coun-
try of origin. Training programs and societies for the
represented countries were surveyed and are shown in the
Table S1. The discussion moved to the need to train non-derma-
tologists such as local nurses and general practitioners. In South
Africa, training programs are active at improving the status and
number of nurse practitioners (160 nurses have been trained
from all over sub-Saharan Africa). These nurses provide primary
care services, which have improved referrals patterns at tertiary
level and improved patient skin care generally at local level.33–35
Another example from South Africa was a patient-run eczema
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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society (South African National Eczema Society; SANEA) offer-
ing direct patient communication and discussion including sim-
ple basic techniques such as how to wash the skin and apply
medication. The case for training traditional healers was also dis-
cussed as some traditional healers are amenable to training in
the essentials of dermatology for working in conjunction with
health services.
It was agreed that telemedicine could be particularly helpful
in the context of SSA.36 Madagascar was shown as a highly con-
nected African country. Established international examples
included the RAFT network (Switzerland)37 delivering tele-
expertise and e-learning to 11 French speaking countries in
Africa since 2000 and the Africa Teledermatology Project (ATP),
which includes 12 countries in Africa.38 Local programs included
examples in Mauritania, Mali and South Africa.39 In Sao Tome,
a project in collaboration with Portugal focuses initially on
albinism. Potential telemedicine applications in AD projects
were discussed including its use for atopic schools, e-learning,
webinars with AD experts with local knowledge of medication
and local practices, apps adjusted for pigmented skin and user-
friendly video tutorials of therapeutic education for patients and
families. Existing apps for tele-expertise–store and forward
(Bogou, RAFT),40 e-learning (Dudal, RAFT)41 and M-health
(PO SCORAD, Dermatite atopique HD) are already providing
help. TPE was shown to be effective in a feasibility study for dia-
betes in Mozambique. Healthcare professionals and education
specialists helped in the design of the project, which was adapted
to local populations. It was implemented through local training
of educators. Overall, TPE objectives (patient empowerment,
achievement of competencies of disease knowledge, diagnosis
and treatment, understanding and acceptance of the disease and
patient autonomy) fit perfectly the AD context, but need local
field adaptation.42,43 The benefit of TPE in terms of reducing
medical costs in chronic diseases was debated.44
Access to essential medicines including emollients
The use of emollients is an important 1st line, basic and crucial
step45 in long-term AD control. In the SSA setting, the use of
local long-term treatments, particularly emollients, is variable.
In some areas, access to essential drugs is assured but in others it
is difficult or impossible, especially if imported products from
branded cosmetic houses are used (e.g. one emollient tube repre-
sents 15% of local minimum monthly salary in Madagascar). In
addition, AD care is hampered by the absence of coverage by
health insurance in some countries. Possible solutions were dis-
cussed such as local emollient production with glycerol, shea
butter or coconut oil.
Topical corticosteroid supplies were reported as variably
available. They can be found as skin lightening/depigmenting
creams, at cheaper prices, on many street vendor stalls or small
corner shops. Their quality cannot be guaranteed, and they may
pose a potential risk of superinfection if used for AD.
For severe cases, systemic steroids are sparsely used for short
periods of time. Methotrexate is available, but in some countries,
the supply is just enough for rheumatology. Cyclosporin is avail-
able in some countries, but rarely used.
Newer drugs to manage AD such as biologicals and small
molecules are currently out of reach of most SSA public medical
systems but are variably available to private medical systems. As
many of the drug trials evaluating the efficacy and safety of these
biologics and small molecule for AD treatments are not under-
taken in Africa, their effects and adverse effects are extrapolated
Table 1 Countries represented at the meeting and the number of trained dermatologists
Country Population
(M)/population
density in h/km2
Number of
dermatologists
Comments on organization of dermatology in health system
Burkina Faso 20/75 30 14 dermatologists in Ouagadougou, 4 in Bobo-Dioulasso
Mauritania 3.6/3 15 14 dermatologists in Nouakchott
Co^te d’Ivoire 25/70 72 65 dermatologists in Abidjan
Mali 18/15 30 23 dermatologists in Bamako
Togo 7/123 15 13 dermatologists in Lome
Niger 21/17 9 6 dermatologists in Niamey
Benin 11/98 14 12 in Cotonou 2 in Parakou
Madagascar 25/43 13 Mostly in Antanarivo
RDC 81/36 18 Dermatologists mostly in Kinshasa
Mozambique 28.8/3.1 15 13 dermatologists in Maputo, 1 in Beira and 1 in Nampula
Rwanda 12.7/486 8 7 dermatologists in Kigali
Senegal 16.2/82 55 42 dermatologists in Dakar
Tanzania 61/64 21 10/21 dermatologists in the two major cities Dar es Salaam and Mwanza
South Africa 58/48 171 Dermatologist in urban areas
Ethiopia 110/99 99 Most dermatologist in Addis Ababa and few in other cities
Uganda 45/183 16 registered Only 13 practicing dermatologists
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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from European and North American findings, which may not be
applicable to the region. New vaccination strategies, still in
experimental stages, might become useful and affordable tools in
the future.46
Design thinking as a possible approach in SSA
Design thinking is a creative innovation process originally used
in the area of design, to improve the look and functionality of
products in line with what the customers want. More recently,
this process is being used to tackle complex social and healthcare
problems. Design thinking has already been used in many pro-
jects in Africa47 (available at http://siteresources.worldbank.org/
WBI/Resources/2137981278955272198/Design_Thinking_for_
SocialInnovation2.pdf).
Design thinking is a person-centred approach that, when
applied to healthcare, involves listening closely to patient’s prob-
lems, desires and needs. Design thinking allows creative solu-
tions to appear from the patients themselves, rather than these
being imposed by the healthcare professional. It also involves
working in collaboration with a multidisciplinary team, which
includes patients and their families, doctors, psychologists, social
workers, nurses and others. The multidisciplinary team must be
trained and have homogeneity in knowledge, attitudes and per-
ceptions. Some skills can be developed and adapted for this pur-
pose, like empathy, integrative thinking, creativity and
experimentation.
A workshop session used design thinking to propose a road-
map for AD.
Summary and roadmap
The meeting highlighted, by field experience, the importance
and burden of AD in SSA, even with limited published data.
AD is one of the most common inflammatory dermatological
diseases in primary, secondary and especially tertiary care in
SSA and has many clinical presentations. Because of the
chronicity of AD and difficulty with treatment availability,
meeting participants acknowledged the burden of AD in der-
matological practice and considered AD as a significant
emerging public health problem in SSA. Therefore, interna-
tional health organizations such as the WHO, dermatology
foundations such as the IFD and international learned soci-
eties such as the ISAD should encourage and support studies
on AD in Africa for better recognition, understanding and
management of the uniqueness of SSA AD. Whilst acknowl-
edging the approach of integrating skin diseases with other
conditions, participants stressed the importance of dermato-
logical conditions specifically.
A design thinking approach could be used to create effective
solutions for the region.
Participants agreed that the difficulties in diagnosis and treat-
ment of AD are related to the lack of medical infrastructure, in
particular, trained primary care workers and certified
dermatologists. They also agreed on the need to develop teleme-
dicine in order to compensate for the low number and uneven
distribution of dermatologists. Research integrating artificial
intelligence to support primary care management with appropri-
ate feedback, and documenting its effectiveness was also sug-
gested.
Particularly important measures should be implemented in
the SSA context for AD:
• Lower taxes on emollients or investigate alternate suppliers,
include emollients in the list of essential medicines at all
levels of healthcare and, in the longer term, produce regio-
nal products. The implementation of a regional survey of
products currently available in SSA was deemed urgent, in
order to make practical proposals.
• For topical corticosteroids, the risk of using over the coun-
ter preparations or those used as skin lightening/depigment-
ing agents has not been thoroughly assessed. Until this is
done, the products should be discouraged for use in AD
and the WHO should promote the use of licensed products
by ensuring their availability at all levels of healthcare as
essential drugs.
• The availability of methotrexate as an essential drug at a ter-
tiary level or under specialist supervision should be sur-
veyed in all SSA countries, with toxicity adequately
managed clinically and biologically.
• Development of AD prevention and education activities
including TPE through e-learning and dedicated apps
• Improving the knowledge of primary healthcare providers
including traditional healers (some already involved for
HIV prevention): publication of an iconographic document
on the main dermatoses diagnosed in pigmented African
skin for primary care workers (as an example see the book-
let ‘Skin diseases, case management algorithms & atlas’ from
Mekelle, Tigray, Ethiopia).
Concerning research initiatives, this first ISAD meeting
devoted to SSA AD has listed the following as top priorities:
• Make specific pan African surveys on emollients, education
programmes for primary care workers, AD scoring scales on
pigmented skin, AD prevalence comparing various pub-
lished diagnostic criteria and patient desires/needs
• Skin barrier function in black African skin
• Impact of AD superinfection on morbidity/mortality
• Keloids and AD (test the hypothesis of less keloids in AD,
TH2 cytokines-fibrosis)
• Scabies/AD (test the hypothesis of TH2 cytokines as limit-
ing parasitic infections)
To improve exchanges between SSA countries with language
barriers, a digital platform, which should be operated in English,
French and Portuguese, could be set up and adapted for e-learn-
ing, telemedicine and research projects.
All initiatives should be implemented in close collaboration
with African dermatologists, the WHO and the IFD and assessed
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at follow-up meetings, in particular, at the next ISAD Meeting in
Seoul, South Korea and at the African Society of Dermatology
and Venereology (ASDV) Meeting and Nairobi, Kenya, both in
2020.
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